Systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC: a prospective study

Treatment with single agent immune checkpoint inhibitors (ICIs) has tremendously changed second line therapy in NSCLC. However, there are still no reliable biomarkers predicting response and survival in this group of patients. PD-L1 revealed to be a correlating, but no perfect marker. Therefore, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Kauffmann-Guerrero, Diego, Kahnert, Kathrin, Kiefl, Rosemarie, Sellmer, Laura, Walter, Julia, Behr, Jürgen, Tufman, Amanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149421/
https://www.ncbi.nlm.nih.gov/pubmed/34035415
http://dx.doi.org/10.1038/s41598-021-90397-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149421/
https://www.ncbi.nlm.nih.gov/pubmed/34035415
http://dx.doi.org/10.1038/s41598-021-90397-y

Ejemplares similares